Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614471 | 0.96 | F10 (0.45) | F10MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL4664291 | 0.93 | F10 (0.47) | F10MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL13546147 | 0.89 | MEN1 (0.41) | F10MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL3611372 | 0.89 | F10 (0.46) | F10MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL8236138 | 0.87 | F10 (0.55) | F10MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL8242467 | 0.86 | F10 (0.48) | F10MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL8245056 | 0.85 | PRSS12 (0.49) | F10MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL8243190 | 0.85 | F10 (0.48) | F10ALDH1A1KMT2AMAPTHTT | |
| SCHEMBL8235723 | 0.84 | F10 (0.49) | F10MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL8236180 | 0.84 | F10 (0.47) | F10MEN1ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004292-A1 | Iminooxazolidine Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| EP-1928868-A1 | IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF | Bayer HealthCare AG (DE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007028520-A1 | IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028520-A1 | IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004292-A1 | Iminooxazolidine Derivatives and Their Use | PPOX, XDH, PNPO | F10 152/4885MEN1 561/4885ALDH1A1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.